Programmed cell death in metabolic syndrome: From molecular mechanisms to therapeutic strategies (Review)
International Journal of Molecular Medicine · 03.09.2026 · 58 (5) · 1-26
DOI: 10.3892/ijmm.2026.5977 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 03.09.2026. Verfasst von Jialin Zhong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, P.R. China. Hauptthemen laut MEDLINE: Metabolic Syndrome, Apoptosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 197 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Metabolic syndrome (MetS) is a clinical syndrome primarily characterized by insulin resistance, integrating central obesity, hyperglycemia, hypertension and dyslipidemia. It is associated with increased risks of type 2 diabetes mellitus, non‑alcoholic fatty liver disease and atherosclerosis. Due to its high prevalence, complex pathogenesis and lack of effective treatments, MetS has become a notable global health issue. Current therapeutic approaches mainly emphasize weight reduction through caloric restriction and increased physical activity, or pharmacological interventions to improve lipid profiles, blood pressure and blood glucose; however, their efficacy remains suboptimal. Growing evidence indicates that programmed cell death (PCD), as a key driver of inflammation, serves a crucial role in the development and progression of MetS. The present review provides a comprehensive overview of recent advances in the understanding of how established and emerging forms of PCD contribute to MetS pathogenesis, including apoptosis, pyroptosis, autophagy, ferroptosis, necroptosis, PANoptosis and disulfidptosis. Particular emphasis is placed on their molecular mechanisms, tissue‑specific functions, regulatory crosstalk and therapeutic potential. Additionally, the present review discusses novel regulatory approaches and potential therapeutic strategies based on PCD network intervention, offering theoretical foundations and directions for developing innovative therapies to prevent and treat MetS and its complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, P.R. China.
Zitieren
APA
Zhong, J., Zhang, M., Zheng, Y., Gong, C., Deng, Y., Sun, L., Zhou, D., Zhou, Q., & Chen, Q. (2026). Programmed cell death in metabolic syndrome: From molecular mechanisms to therapeutic strategies (Review). International Journal of Molecular Medicine, 58(5), 1-26. https://doi.org/10.3892/ijmm.2026.5977
Vancouver
Zhong J, Zhang M, Zheng Y, Gong C, Deng Y, Sun L, et al. Programmed cell death in metabolic syndrome: From molecular mechanisms to therapeutic strategies (Review). International Journal of Molecular Medicine. 2026;58(5):1-26. doi:10.3892/ijmm.2026.5977
BibTeX
@article{Zhong2026,
author = {Zhong, Jialin and Zhang, Maofu and Zheng, Yafang and Gong, Cuicui and Deng, Yasheng and Sun, Lisha and Zhou, Dongqi and Zhou, Qian and Chen, Qiu},
title = {Programmed cell death in metabolic syndrome: From molecular mechanisms to therapeutic strategies (Review)},
journal = {International Journal of Molecular Medicine},
year = {2026},
volume = {58},
number = {5},
pages = {1--26},
doi = {10.3892/ijmm.2026.5977}
}
EUVIMED